U.S. Food and Drug Administration approve expanded indication for Caldolor to include postoperative pain, strengthening non-opioid pain management options.
Written By: Mahathi Palivela, PharmD
Reviewed By: Pharmacally Editorial Team
Cumberland Pharmaceuticals Inc. has announced that the U.S. Food and Drug Administration has approved an expanded indication for its intravenous ibuprofen product, Caldolor, adding postoperative pain management to its label.
The decision broadens the drug’s use across both adult and pediatric patients aged 3 months and older. Under the updated labeling, Caldolor is now indicated for the management of mild to moderate pain, as well as moderate to severe pain as an adjunct to opioid analgesics, including in postoperative settings. It also retains its indication for fever reduction.
The approval marks a regulatory step that aligns with increasing clinical focus on reducing opioid use in surgical and acute care environments. By formally including postoperative pain, the FDA’s decision positions Caldolor more directly within perioperative treatment protocols that emphasize multimodal, opioid-sparing approaches.
Cumberland paired the regulatory update with the launch of a redesigned Caldolor website aimed at healthcare professionals. According to the company, the platform highlights the expanded indication and provides resources on postoperative pain management, including the role of intravenous non-opioid therapies and strategies supporting opioid stewardship.
The website also includes clinical and prescribing information, along with guidance on dosing, safety, and reimbursement access, including J-Code support.
Postoperative pain remains a persistent challenge across surgical settings, particularly as healthcare systems seek to balance effective pain control with efforts to limit opioid exposure. The company’s updated digital resources reflect this evolving landscape, with a focus on integrating non-opioid options into standard care pathways.
Caldolor, an intravenous formulation of ibuprofen, was previously approved for pain management and fever reduction and is recognized as the first FDA-approved IV therapy for fever. The expanded indication does not alter its established safety profile, which includes contraindications in patients with known hypersensitivity to NSAIDs and in those undergoing coronary artery bypass graft surgery.
The company stated that healthcare professionals can access full prescribing and safety information through the updated website, alongside additional support resources for medical and product-related inquiries.
The FDA’s approval represents a targeted expansion rather than a new product entry, but it underscores the ongoing shift in perioperative care toward broader use of non-opioid analgesic options.
Reference
Mahathi Palivela is pursuing PharmD and has a strong interest in Clinical Pharmacy and Patient safety. She is passionate about handling and analyzing patient data, and translating clinical insights into clear, meaningful summaries. She aims to apply this interest in Medical Writing and Pharmacovigilance, focusing on improving patient outcomes through careful data interpretation and communication .